Tirzepatide dosing and titration schedule, explained

Like semaglutide, tirzepatide is built up gradually rather than started at its effective dose. But because tirzepatide acts on two gut-hormone receptors (GLP-1 and GIP) rather than one, its schedule and its ceiling dose are structured a little differently — worth understanding before you compare notes with someone on semaglutide.

The dual-receptor difference, briefly

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is part of why its trials have reported some of the largest average weight-loss figures in the class². That dual action doesn't change the logic behind titration, though — dose-related GI side effects are still the reason the drug is stepped up slowly rather than started at the top.

The general shape of the schedule

The pivotal SURMOUNT-1 obesity trial tested tirzepatide starting at a low dose and escalating roughly every four weeks, through a series of steps, up to one of three maintenance doses studied — 5 mg, 10 mg, or 15 mg weekly — with the higher maintenance doses producing larger average weight reductions¹². The label reflects that same staged approach: a low starting dose meant only to ease tolerability, not to treat, followed by scheduled increases toward a target maintenance dose your prescriber sets based on your response and tolerability⁵. Tirzepatide's approved schedule tops out higher than semaglutide's — up to 15 mg weekly — which is one reason it's worth pricing your maintenance dose specifically rather than assuming a flat monthly number; see how much does tirzepatide cost for that breakdown. For the exact concentration and volume behind every step, see our dosing chart.

What the steps feel like

The same pattern applies as with any GLP-1 titration: a bump in GI symptoms after a dose increase that typically settles before the next step. A systematic review and meta-analysis of GLP-1 receptor agonist tolerability across nearly 100,000 patients found this class-wide pattern of manageable, mostly GI-driven adverse events rather than escalating severity over time in most patients³. What isn't part of the expected pattern is symptoms that worsen rather than settle, or severe, persistent vomiting or abdominal pain — see GLP-1 side effects: what to expect for the full breakdown of common versus red-flag symptoms.

Individualizing the pace

Not everyone needs to reach 15 mg, and not everyone should rush there. Some patients titrate more slowly, spend longer at an intermediate dose, or land on a lower maintenance dose that works well for them with fewer side effects. That's a legitimate clinical outcome, not a failure to 'complete' the schedule — the trial data itself shows meaningful weight loss at 5 mg and 10 mg, not only at the top dose¹. If a step is genuinely hard to tolerate, that's a conversation for your prescriber, not a reason to self-adjust or skip doses.

Technique and timing matter alongside the schedule

How you inject affects how consistently the medication is absorbed, and site rotation reduces local irritation over months of weekly injections. We cover the mechanics in how to inject semaglutide and tirzepatide. If you're also weighing how this schedule interacts with alcohol, GLP-1 and alcohol is worth reading, since slowed gastric emptying can change how alcohol affects you during titration. And if you're comparing this molecule-by-molecule against semaglutide's schedule, see semaglutide dosing and titration side by side. This is general information about how the schedule works, not a substitute for your prescriber's specific instructions.